Skip to main content

Table 2 Details of medically managed patients

From: Long term evaluation of a multidisciplinary trigeminal neuralgia service

 

1st visit

MDT clinic

Final follow up

p

n

132

132

116

 

Drug (%)

   

<0.001

No drugs

4 (3.0)

18 (13.6)

25 (21.6)

 

Monotherapy

102 (77.3)

81 (61.4)

70 (60.3)

 

Polytherapy

26 (19.7)

33 (25.0)

21 (18.1)

 

CBZ (%)

54 (40.9)

31 (23.5)

22 (19.0)

<0.001

OXC (%)

56 (42.4)

61 (46.2)

49 (42.2)

0.769

GAB (%)

8 (6.1)

6 (4.5)

4 (3.4)

0.622

LAM (%)

16 (12.1)

32 (24.2)

26 (22.4)

0.050

PHE (%)

0 (0)

0 (0)

0 (0)

NA

BAC (%)

5 (3.8)

2 (1.5)

2 (1.7)

0.412

LID (%)

2 (1.5)

2 (1.5)

5 (4.3)

0.256

Other drug (%)

14 (10.6)

15 (11.4)

116 (100.0)

<0.001

Pain (%)

   

<0.001

Pain free off drugs

0 (0.0)

 

18 (15.5)

 

Pain free with drugs

6 (4.5)

 

10 (8.6)

 

Mild pain

14 (10.6)

 

50 (43.1)

 

Moderate pain

19 (14.4)

 

25 (21.6)

 

Severe pain

93 (70.5)

 

13 (11.2)

 
  1. CBZ Carbamazepine, OXC Oxcarbazepine, GAB Gabapentin, LAM Lamotrigine, PHE Phenytoin, BAC Baclofen, LID Lidocaine